(r)-n6-Phenyl-2-propyladenosine

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (r)-n6-Phenyl-2-propyladenosine
• 英文别名: (2R,3R,4S,5R)-2-(6-anilino-2-propylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• 化学式: C₁₉H₂₃N₅O₄
• 分子量: 385.4
• InChiKey: SDPVHMNZMGSKTC-BGIGGGFGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Use of tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) for the manufacture of a therapeutic composition
  申请人：THE KENNEDY INSTITUTE OF RHEUMATOLOGY

  公开号：EP1170017A1

  公开（公告）日：2002-01-09

  Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed are compositions comprising a TNFα antagonist and a VEGF antagonist. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.

  本研究公开了治疗和/或预防由 TNF 介导的疾病的方法。还公开了包含 TNFα 拮抗剂和血管内皮生长因子拮抗剂的组合物。TNF介导的疾病包括类风湿性关节炎、克罗恩病以及与移植相关的急性和慢性免疫疾病。
• Methods of treating vascular disease with TNF antagonists
  申请人：THE KENNEDY INSTITUTE OF RHEUMATOLOGY

  公开号：EP1460087A1

  公开（公告）日：2004-09-22

  A method of treating or preventing a cardiovascular and/or a cerebrovascular disorder in an individual is disclosed. Also disclosed is a method for treating and/or preventing a thrombotic disorder in an individual. Further disclosed is a method of decreasing plasma fibrinogen in an individual.

  本发明公开了一种治疗或预防个人心血管和/或脑血管疾病的方法。还公开了一种治疗和/或预防个人血栓性疾病的方法。还公开了一种降低人体血浆纤维蛋白原的方法。
• Anti-TNF antibodies and methotrexate in the treatment of autoimmune diseases
  申请人：THE KENNEDY INSTITUTE OF RHEUMATOLOGY

  公开号：EP1593393A2

  公开（公告）日：2005-11-09

  Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.

  本研究公开了治疗和/或预防由 TNF 介导的疾病的方法。还公开了一种包含甲氨蝶呤和抗肿瘤坏死因子抗体的组合物。TNF介导的疾病包括类风湿性关节炎、克罗恩病以及与移植相关的急性和慢性免疫疾病。
• TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease
  申请人：The Kennedy Institute of Rheumatology, England

  公开号：US20020010180A1

  公开（公告）日：2002-01-24

  Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.

  本研究公开了治疗和/或预防由 TNF 介导的疾病的方法。 还公开了一种包含甲氨蝶呤和抗肿瘤坏死因子抗体的组合物。 TNF介导的疾病包括类风湿性关节炎、克罗恩病以及与移植相关的急性和慢性免疫疾病。
• METHODS OF PREVENTING OR TREATING CARDIOVASCULAR, CEREBROVASCULAR AND THROMBOTIC DISORDERS WITH TUMOR NECROSIS FACTOR ANTAGONISTS
  申请人：——

  公开号：US20020081306A1

  公开（公告）日：2002-06-27

  A method of treating or preventing a cardiovascular and/or a cerebrovascular disorder in an individual is disclosed. Also disclosed is a method for treating and/or preventing a thrombotic disorder in an individual. Further disclosed is a method of decreasing plasma fibrinogen in an individual.

  本发明公开了一种治疗或预防个人心血管和/或脑血管疾病的方法。还公开了一种治疗和/或预防个人血栓性疾病的方法。还公开了一种降低人体血浆纤维蛋白原的方法。